Federal Circuit dismisses Amgen’s Neulasta appeal

30-07-2019

Federal Circuit dismisses Amgen’s Neulasta appeal

jhvephoto / Shutterstock.com

California-based Amgen is barred from succeeding on its patent infringement claim against Coherus Biosciences, according to the US Court of Appeals for the Federal Circuit.


Amgen, Coherus BioSciences, US Court of Appeals for the Federal Circuit, Neulasta, USPTO, aBLA, FDA, biologics, estoppel

LSIPR